CDNA:NSD-Caredx Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 23.48

Change

-2.59 (-9.93)%

Market Cap

USD 1.38B

Volume

1.32M

Avg Analyst Target

USD 63.50 (+170.44%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


CDNA Stock Forecast & Price:
Based on the Caredx Inc stock forecasts from 4 analysts, the average analyst target price for Caredx Inc is USD 63.50 over the next 12 months. Caredx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Caredx Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Caredx Inc’s stock price was USD 23.48. Caredx Inc’s stock price has changed by -2.09% over the past week, -10.59% over the past month and -70.78% over the last year.

About Caredx Inc (CDNA:NSD)

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-09 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

-8.18 (-3.67%)

USD35.03B 48.90 30.28
IDXX IDEXX Laboratories Inc

-18.40 (-4.52%)

USD33.95B 52.41 36.64
ICLR ICON PLC

-1.41 (-0.61%)

USD18.90B 125.99 23.74
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
EXAS EXACT Sciences Corporation

-3.76 (-8.03%)

USD8.28B N/A -18.67
SYNH INC Research Holdings Inc

-1.03 (-1.50%)

USD6.98B 33.98 14.39
GH Guardant Health Inc

-5.54 (-10.17%)

USD5.41B N/A -15.33
MEDP Medpace Holdings Inc

+0.47 (+0.28%)

USD5.21B 28.64 21.01
NTRA Natera Inc

-1.34 (-2.57%)

USD5.04B N/A -8.31
TWST Twist Bioscience Corp

-8.03 (-14.20%)

USD2.97B N/A -11.16

ETFs Containing CDNA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.37% 45% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.37% 45% F 24% F
Trailing 12 Months  
Capital Gain -69.58% 35% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.58% 35% F 20% F
Trailing 5 Years  
Capital Gain 1,652.24% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,652.24% 100% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 122.92% 89% B+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 122.92% 89% B+ 96% A
Risk Return Profile  
Volatility (Standard Deviation) 191.80% 16% F 6% F
Risk Adjusted Return 64.09% 84% B 90% A-
Market Capitalization 1.38B 67% D+ 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.85 38% F 33% F
Price / Cash Flow Ratio -71.69 98% A+ 88% B+
EV/EBITDA -28.61 98% A+ 92% A-
Management Effectiveness  
Return on Equity -15.03% 67% D+ 39% F
Return on Invested Capital -7.61% 67% D+ 38% F
Return on Assets -7.28% 63% D 34% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.02 29% F 29% F
Short Percent 8.20% 24% F 22% F
Beta 0.88 71% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.